<DOC>
	<DOCNO>NCT03061474</DOCNO>
	<brief_summary>The purpose research study test whether nicotinamide , also know vitamin B3 niacinamide , take high dos , reduce phosphorylation tau ( protein accumulate neurofibrillary tangle ) people Mild Cognitive Impairment mild Alzheimer 's disease ( AD ) dementia .</brief_summary>
	<brief_title>Nicotinamide Early Alzheimer 's Disease Treatment</brief_title>
	<detailed_description>Nicotinamide , amide nicotinic acid ( vitamin B3/niacin ) , oral therapy wealth clinical data variety therapeutic area , include preliminary data support safety Alzheimer 's disease ( AD ) . Preclinical work mouse model develop plaque tangle support hypothesis nicotinamide act histone deacetylase ( HDAC ) inhibitor reduce phosphorylation tau . The study implement group sequential design , incorporate futility analysis go/no-go decision conditional cerebral spinal fluid CSF biomarker outcomes 12-months . The primary outcome trial change p-tau231 . This study timeline include screen phase 60 day treatment phase expect last 48 week include 4 study visit . An additional 12-month treatment follow-up period plan , contingent upon `` go '' decision base primary outcome ( CSF p-tau231 ) one plan secondary outcome ( CSF p-tau181 )</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>1 . Mild Cognitive Impairment ( MCI ) dementia due Alzheimer 's disease ( AD ) 2 . Biomarker criterion : Cerebral Spinal Fluid ( CSF ) Amyloid Beta 142 ( Aβ42 ) &lt; = 200 pg/mL , A ratio total tau Aβ42 ≥ 0.39 , A ratio ptau181to Aβ42 ≥ 0.14 . 3 . MiniMental State Exam ( MMSE ) ≥ 20 4 . Blood laboratory , urinalysis , electrocardiogram within normal limit deem clinically significant site investigator 5 . Stable medication ( include approve AD therapy ) least 4 week 6 . At least 6 year education 7 . Able swallow oral tablet 8 . Speaks English fluently 9 . Available qualified study partner ( ≥3 time per week inperson communication participant ) 1 . Active neurological psychiatric diagnosis AD may affect cognition and/or function . ( Obstructive sleep apnea permit , treat . ) 2 . Inability undergo lumbar puncture , include use Coumadin , novel oral anticoagulant , clopidogrel , dipyridamole . Use aspirin &lt; = 325mg daily permit . 3 . Hachinski ischemic scale &gt; 4 4 . Magnetic Resonance Imaging ( MRI ) incompatibility 5 . MRI evidence cortical stroke &gt; 1cm , superficial siderosis , extensive white matter hyperintensity ( Cardiovascular Health Study score 78+ ) 6 . Diagnosis cancer previous 5 year ( exception basal squamous cell carcinoma ) 7 . Geriatric Depression Scale ( GDS ) score &gt; 6 8 . History within past 5 year alcohol substance use disorder 9 . Laboratory evidence clinically significant abnormality may interfere study assessment 10 . Active partial total malabsorptive disease ( e.g. , celiac disease ) 11 . Resides skilled nursing facility 12 . Participation clinical trial potential diseasemodifying therapy AD previous 6months ( time last investigational drug administration baseline current study ) 13 . Pregnant , lactate child bear potential ( , woman must 2 year postmenopausal surgically sterile consider child bear potential ) . 14 . Unwillingness abstain overthecounter nicotinamide duration trial</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Mild Cognitive Impairment</keyword>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Nicotinamide</keyword>
	<keyword>Niacinamide</keyword>
	<keyword>Niacin</keyword>
	<keyword>Nicotinic Acids</keyword>
	<keyword>Vitamin</keyword>
	<keyword>Neurodegenerative Diseases</keyword>
	<keyword>Tauopathies</keyword>
	<keyword>Dementia</keyword>
</DOC>